Potential role of IL-17 blocking agents in the treatment of severe COVID-19?

Bulat, Vedrana; Situm, Mirna; Azdajic, Marija Delas; Likic, Robert

Bulat, Vedrana; Situm, Mirna; Azdajic, Marija Delas; Likic, Robert.

Bulat V; Department of Dermatology and Venereology, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Situm M; Department of Dermatology and Venereology, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Azdajic MD; Department of Dermatology and Venereology, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Likic R; School of Medicine, University of Zagreb, Zagreb, Croatia.

Br J Clin Pharmacol ; 87(3): 1578-1581, 2021 03.

Article in English | MEDLINE | ID: covidwho-632887

Subject(s)

COVID-19 Drug Treatment; Interleukin-17/antagonists & inhibitors; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; Humans; Th17 Cells/drug effects

Keywords

COVID-19; IL-17 blocking agents; SARS-CoV-2; brodalumab; ixekizumab; secukinumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-17 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Br J Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: Bcp.14437

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google